Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
NCT04942886Enrolling by invitation
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of entecavir in hepatitis B (HBV) (2 arms), sponsored by Seoul St. Mary's Hospital. Primary endpoint: Rate of HBV reactivation at 3 years. Started Aug 2021; status: enrolling by invitation.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04942886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942886.